Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents-Reference-Cited by-同舟云学术

Assessment of Novel Mesothelin-Specific Human Antibody Domain VH-Fc Fusion Proteins-Based PET Agents

Published:2023-11-08 Issue:46 Volume:8 Page:43586-43595
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Sun Zehua¹,Jaswal Ambika P.²,Chu Xiaojie¹,Rajkumar Harikrishnan³,Cortez Angel G.³,Edinger Robert³,Rose Max³,Josefsson Anders³⁴^ORCID,Bhise Abhinav³⁴,Huang Ziyu³,Ishima Rieko⁵^ORCID,Mellors John W¹,Dimitrov Dimiter S.¹,Li Wei¹,Nedrow Jessie R.³⁴^ORCID

Affiliation:

1. Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States

2. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States

3. Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States

4. Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States

5. Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States

Funder

Medical Center, University of Pittsburgh

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.3c04492

Reference31 articles.

1. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium

2. Application of Mesothelin Immunostaining in Tumor Diagnosis

3. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

4. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer

5. MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer